Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic Malignancies

June 12th 2020

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Dr. Brody on Modulating Fas Signaling to Prevent Relapse in Hematologic Malignancies

June 12th 2020

Joshua Brody, MD, discusses Fas and its impact on bystander killing in patients with non-Hodgkin lymphoma.

Dr. DiNardo on Timing and Impact of Response to Venetoclax Combinations in AML

June 11th 2020

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

June 11th 2020

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

June 10th 2020

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (Yescarta) in patients with relapsed/refractory follicular lymphoma.

Dr. DiNardo on Timing and Impact of Response to Venetoclax Combinations in AML

June 10th 2020

Courtney DiNardo, MD, MSCE, discusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Dr. Furman on Differences Between BTK Inhibitors in B-Cell Malignancies

June 10th 2020

Richard R. Furman, MD, discusses differences among the different available BTK inhibitors for use in patients with B-cell malignancies.

Acalabrutinib Showcases Long-Term Tolerability Across B-Cell Malignancies

June 9th 2020

Richard R. Furman, MD, discusses the findings from the analysis and highlights the differences between first- and second-generation BTK inhibitors in CLL.

CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma

June 7th 2020

This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma. Join us Tuesday, June 30, 2020 at 7 PM EST.

Dr. Abdul-Hay on the Use of HCT-CI to Guide Transplant Eligibility in ALL

June 6th 2020

Mohammad Maher Abdul-Hay, MD, discusses the use of the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) to guide transplant eligibility in acute lymphoblastic leukemia (ALL).

Pooled Analysis Shows Predictive Features Linked With Variable Timing of Response to Venetoclax in AML

June 5th 2020

Courtney DiNardo, MD, MSCE, discusses the results of the analysis evaluating the timing of response to venetoclax-based combinations, and related disease features, in older patients with AML.

Experts Provide Tips on Harnessing MRD to Guide ALL Therapy

June 4th 2020

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemia provided insight on how they use minimal or measurable residual disease (MRD) to guide treatment decisions, including transplantation and choice of therapy in patients who demonstrate MRD positivity after induction and first- and subsequent-line therapies.

Seeking a New Path for AL Amyloidosis

June 4th 2020

Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis and is characterized by rapidly progressive organ failure and eventually patient demise, if not promptly recognized and treated.

Dr. Sekeres on the Need for Novel Combinations in Higher-Risk MDS/CMML and Low-Blast AML

June 4th 2020

Mikkael A. Sekeres, MD, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).

Pevonedistat/Azacitidine Shows Favorable Activity in Higher-Risk MDS/CMML, Low-Blast AML

June 3rd 2020

The combination of pevonedistat and azacitidine led to a trend toward improved event-free survival and a numerical improvement in overall survival versus azacitidine alone in patients with higher-risk myelodysplastic syndrome/chronic myelomonocytic leukemia, and low-blast acute myelogenous leukemia.

Dr. DiNardo on the Role of Venetoclax in AML

June 3rd 2020

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).

Dr. Hamdan on Choosing Among ABVD Versus A+AVD in Hodgkin Lymphoma

June 2nd 2020

Ayad Hamdan, MD, discusses factors to consider when choosing between brentuximab vedotin (Adcetris), doxorubicin, vinblastine, and dacarbazine versus AVD plus bleomycin in patients with Hodgkin lymphoma.

Dr. Cutler on Remaining Challenges in GVHD

June 2nd 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses remaining challenges in graft-versus-host disease.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL

May 31st 2020

Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

AMG 330 Shows Promise in Treating Relapsed/Refractory AML

May 30th 2020

Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia, with cytokine release syndrome as the most frequent and expected adverse event.